Evidence map›Paper›PMID 41792931›Full record

ArticleJournal of clinical apheresis2026

Guidance for Documentation of Therapeutic Apheresis Interventions in the Medical Record: An American Society for Apheresis (ASFA) Practice Perspective.

Chester Andrzejewski, Yanhua Li, Ding Wen Wu, Gustaaf De Ridder, Jan C Hofmann, Susan Knight, Sajjad Hassan, Nicole A Aqui, Walter Linz

Abstract read
In one paragraph

Article in Journal of clinical apheresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chester AndrzejewskiSystem Blood Banking and Transfusion/Apheresis Medicine Services, Department of Pathology, Baystate Medical Center, Baystate Health, Springfield, Massachusetts, USA.ORCID https://orcid.org/0000-0003-3120-9010
Yanhua LiDivision of Transfusion Medicine, Department of Medicine, UMass Memorial Medical Center, Worcester, Massachusetts, USA.
Ding Wen WuDepartment of Pathology and Laboratory Medicine, NYU Langone Hospital-Brooklyn, New York, New York, USA.ORCID https://orcid.org/0000-0001-9199-3092
Gustaaf De RidderSystem Transfusion Services, Department of Laboratory Medicine 19-30, Geisinger Health, Danville, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-1622-7659
Jan C HofmannDepartment of Pathology and Laboratory Medicine, University of California, San Francisco, California, USA.
Susan KnightVersiti/Medical Sciences Institute, Milwaukee, Wisconsin, USA.
Sajjad HassanSystem Blood Banking and Transfusion/Apheresis Medicine Services, Department of Pathology, Baystate Medical Center, Baystate Health, Springfield, Massachusetts, USA.ORCID https://orcid.org/0000-0002-7264-5989
Nicole A AquiDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Walter LinzOklahoma Blood Institute, Oklahoma City, Oklahoma, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2007, the American Society for Apheresis (ASFA) published guidance for physician documentation related to oversight of therapeutic apheresis (TA). Due to 21st century changes in healthcare delivery, the ASFA Board of Directors (BOD) charged its Public Affairs and Advocacy Committee (PAAC) to coordinate a review and update of the guidance. PAAC members reviewed minutes from various ASFA committees' earlier deliberations and sought additional information from the medical and general literature and regulatory/professional organizations involved with medical records documentation as well as from ASFA membership. A draft document was developed, reviewed, and approved by pertinent parties with changes incorporated into the guidance revision. Major change agents impacting TA documentation were identified including the importance of multidisciplinary care teams, the adoption of telemedicine in TA delivery, and the challenges highlighted by the SARS-CoV-2 pandemic. Formats involving TA documentation scenarios related to initial TA consultations and subsequent care activities by TA staff were developed. The introduction of new technologies, the advancing and mandating of electronic medical records (EMRs) adoption and a renewed emphasis on the team-based nature of healthcare delivery have all impacted TA services. Revised documentation formatting practices related to these changes, not only for physicians' involvement but recognition and inclusion of other members of multidisciplinary teams participating in TA, should be incorporated into TA operations. Such revisions can potentially enhance patient care and provide a foundation for TA-related biovigilance activities.

Indexed as

Blood Component RemovalDocumentationMedical RecordsCOVID-19Electronic Health RecordsHumansSARS-CoV-2Societies, MedicalTelemedicineUnited Statesbenchmarkingbiovigilanceclinical reporting formatstelapheresis

Identifiers

PMID41792931
PMCPMC12966628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.